Our study showed that circAGAP1 inhibition suppressed ccRCC tumor progression through E2F3, further demonstrating the regulatory ability of the circAGAP1/E2F3 axis in ccRCC. The gene discussed is E2F3; the disease is nonpapillary renal cell carcinoma.